Blog
RSS FeedPosted by Michael Wonder on 01 Dec 2024
BC man calls on federal, provincial governments to cover his costly, life saving cancer treatment
30 November 2024 - Pharmaceutical company Novartis says a five dose treatment costs about $135K. ...
Posted by Michael Wonder on 22 Oct 2024
Nine provinces approve accelerated public reimbursement of diffuse large B-cell lymphoma treatment under new early access process
21 October 2024 - AbbVie today announced that nine provinces have provided accelerated public coverage of Epkinly. ...
Posted by Michael Wonder on 18 Jul 2024
BC doctor calls on the province to cover obesity medications
17 July 2024 - A petition from Dr. Ali Zentner asking for more PharmaCare coverage has received almost 1,000 signatures. ...
Posted by Michael Wonder on 08 Feb 2024
HLS announces that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan
6 February 2024 - Public reimbursement for Vascepa is now available in Ontario, Quebec, British Columbia, Saskatchewan, New Brunswick, Northwest Territories, ...
Posted by Michael Wonder on 22 Dec 2023
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) receive public listing for patients with advanced endometrial carcinoma that is not MSI-H or dMMR
21 December 2023 - Merck and Eisai announce that Keytruda plus Lenvima, is now reimbursed with clinical criteria and conditions ...
Posted by Michael Wonder on 26 Oct 2023
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) is available for the first-line treatment of adult patients with advanced or metastatic renal cell carcinoma
25 October 2023 - Merck and Eisai announced today that Keytruda, an anti-PD-1 therapy, in combination with Lenvima, the multiple receptor ...
Posted by Michael Wonder on 27 Jul 2023
British Columbia to publicly reimburse Albrioza for the treatment of ALS
19 July 2023 - Amylyx Pharmaceuticals Canada announced today that the Company has entered into a Product Listing Agreement with British ...
Posted by Michael Wonder on 08 Mar 2023
Jazz Pharmaceuticals secures eight additional provincial reimbursements for Vyxeos for treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes
8 March 2023 - Jazz Pharmaceuticals announced today that Vyxeos (daunorubicin and cytarabine liposome for injection) is now included on eight ...
Posted by Michael Wonder on 07 Dec 2022
Tukysa (tucatinib) reimbursed in British Columbia for the treatment of patients with advanced or metastatic HER2 positive breast cancer
6 December 2022 - BC is the third province to add Tukysa to its provincial dormulary. ...
Posted by Michael Wonder on 09 Sep 2022
B.C. family grateful for expanded funding to cystic fibrosis drug, but questions why it took so long
7 September 2022 - B.C. is last Canadian jurisdiction to fund Trikafta for patients with cystic fibrosis age 6 to 11. ...
Posted by Michael Wonder on 08 Sep 2022
British Colombia expands children’s access to ‘transformational’ cystic fibrosis drug
7 September 2022 - A week after a B.C. family went public with its plea for a life-changing drug for ...
Posted by Michael Wonder on 08 Aug 2022
Funding for lifesaving drug denied by B.C. health authority as couple struggles to fund their portion
7 August 2022 - Entrectinib, a targeted drug that had shown positive results in tumours that had the same gene expression, ...
Posted by Michael Wonder on 17 May 2022
Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Canada’s Ajovy (fremanezumab), for the preventive treatment of migraine in adults
17 May 2022 - Teva Canada welcomes the recently announced public formulary coverage for Ajovy (fremanezumab) by Ontario, British Columbia, ...
Posted by Michael Wonder on 28 Apr 2022
Baqsimi (nasal glucagon), rescue treatment for severe hypoglycaemia now covered in British Colombia, Alberta & Saskatchewan
27 April 2022 - Lilly Canada is pleased to announce that as of 5 April 2022, Baqsimi (glucagon nasal powder) ...
Posted by Michael Wonder on 21 Apr 2022
Astellas announces reimbursement for Xospata (gilteritinib) in most provinces for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation
21 April 2022 - Having access to an additional treatment option offers hope for Canadian adult AML patients with relapsed ...